- Home
- AURA
as 02-21-2025 12:31pm EST
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 398.1M | IPO Year: | 2021 |
| Target Price: | $23.00 | AVG Volume (30 days): | 139.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.63 - $12.38 | Next Earning Date: | 03-26-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aura Biosciences Inc. (AURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| de los Pinos Elisabet | AURA | See Remarks | Feb 18 '25 | Sell | $7.75 | 20,221 | $156,795.66 | 482,440 | |
| Plavsic Mark | AURA | Chief Technology Officer | Feb 18 '25 | Sell | $7.75 | 2,151 | $16,670.25 | 209,456 | |
| Hopkins Janet Jill | AURA | Chief Medical Officer | Feb 18 '25 | Sell | $7.75 | 2,534 | $19,638.50 | 269,794 | |
| de los Pinos Elisabet | AURA | See Remarks | Jan 21 '25 | Sell | $7.67 | 15,955 | $122,381.23 | 482,440 | |
| Elazzouzi Amy | AURA | Vice President, Finance | Jan 21 '25 | Sell | $7.67 | 1,001 | $7,679.17 | 38,442 |
Latest Aura Biosciences Inc. News
AURA Breaking Stock News: Dive into AURA Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
GlobeNewswire
3 months ago
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
GlobeNewswire
3 months ago
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Simply Wall St.
4 months ago
One Aura Biosciences Insider Raised Stake By 232% In Previous Year
MT Newswires
4 months ago
Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing
GlobeNewswire
4 months ago
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Simply Wall St.
5 months ago
Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58%
Zacks
5 months ago
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
Compare AURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AURA Aura Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.